| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity J Barretina, G Caponigro, N Stransky, K Venkatesan, AA Margolin, S Kim, ... Nature 483 (7391), 603-607, 2012 | 7697 | 2012 |
| The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment HF Clark, AL Gurney, E Abaya, K Baker, D Baldwin, J Brush, J Chen, ... Genome research 13 (10), 2265-2270, 2003 | 511 | 2003 |
| A highly conserved enhancer in the Dlx5/Dlx6Intergenic region is the site of cross-regulatory interactions betweenDlx genes in the embryonic forebrain T Zerucha, T Stühmer, G Hatch, BK Park, Q Long, G Yu, A Gambarotta, ... Journal of neuroscience 20 (2), 709-721, 2000 | 410 | 2000 |
| DLX‐1, DLX‐2, and DLX‐5 expression define distinct stages of basal forebrain differentiation DD Eisenstat, JK Liu, M Mione, W Zhong, G Yu, SA Anderson, I Ghattas, ... Journal of Comparative Neurology 414 (2), 217-237, 1999 | 346 | 1999 |
| Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition J Murai, Y Feng, KY Guoying, Y Ru, SW Tang, Y Shen, Y Pommier Oncotarget 7 (47), 76534, 2016 | 258 | 2016 |
| Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer CA Stewart, P Tong, RJ Cardnell, T Sen, L Li, CM Gay, F Masrorpour, ... Oncotarget 8 (17), 28575, 2017 | 179 | 2017 |
| Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism H Lu, Y Xue, GK Yu, C Arias, J Lin, S Fong, M Faure, B Weisburd, X Ji, ... Elife 4, e06535, 2015 | 136 | 2015 |
| The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo DL Menezes, P Taverna, MR Jensen, T Abrams, D Stuart, GK Yu, D Duhl, ... Molecular cancer therapeutics 11 (3), 730-739, 2012 | 92 | 2012 |
| Novel compositions and methods in cancer A Lai, A Fanidi, R Booher, G Yu, E Moler, M Rowe US Patent App. 11/403,116, 2007 | 91 | 2007 |
| The essential transcription factor, Mcm1, is a downstream target of Sln1, a yeast" two-component" regulator G Yu, RJ Deschenes, JS Fassler Journal of Biological Chemistry 270 (15), 8739-8743, 1995 | 51 | 1995 |
| SPT13 (GAL11) of Saccharomyces cerevisiae negatively regulates activity of the MCM1 transcription factor in Ty1 elements G Yu, JS Fassler Molecular and cellular biology, 1993 | 50 | 1993 |
| Evidence that GRIP, a PDZ-domain protein which is expressed in the embryonic forebrain, co-activates transcription with DLX homeodomain proteins G Yu, T Zerucha, M Ekker, JLR Rubenstein Developmental Brain Research 130 (2), 217-230, 2001 | 46 | 2001 |
| The Saccharomyces cerevisiae SPT14 gene is essential for normal expression of the yeast transposon, Ty, as well as for expression of the HIS4 gene and several … JS Fassler, W Gray, JP Lee, G Yu, G Gingerich Molecular and General Genetics MGG 230, 310-320, 1991 | 44 | 1991 |
| SEMA4D in cancer diagnosis, detection and treatment A Lai, A Fanidi, R Booher, C Tse, X Xu, G Yu, E Moler, M Rowe US Patent 7,919,246, 2011 | 25 | 2011 |
| Induction of ER stress by an AAV5 BDD FVIII construct is dependent on the strength of the hepatic-specific promoter S Fong, B Handyside, CR Sihn, S Liu, L Zhang, L Xie, R Murphy, ... Molecular Therapy-Methods & Clinical Development 18, 620-630, 2020 | 24 | 2020 |
| Neurofilament light is a treatment‐responsive biomarker in CLN2 disease Y Ru, C Corado, RK Soon Jr, AC Melton, A Harris, GK Yu, N Pryer, ... Annals of Clinical and Translational Neurology 6 (12), 2437-2447, 2019 | 24 | 2019 |
| Assessment of predicted enzymatic activity of α‐N‐acetylglucosaminidase variants of unknown significance for CAGI 2016 WT Clark, L Kasak, C Bakolitsa, Z Hu, G Andreoletti, G Babbi, Y Bromberg, ... Human mutation 40 (9), 1519-1529, 2019 | 14 | 2019 |
| Utilizing ExAC to assess the hidden contribution of variants of unknown significance to Sanfilippo Type B incidence WT Clark, GK Yu, M Aoyagi-Scharber, JH LeBowitz PLoS One 13 (7), e0200008, 2018 | 14 | 2018 |
| Novel compositions and methods in cancer G Yu, E Moler, M Rowe US Patent App. 11/408,131, 2007 | 11 | 2007 |
| Identifying therapeutic drug targets using bidirectional effect genes K Estrada, S Froelich, A Wuster, CR Bauer, T Sterling, WT Clark, Y Ru, ... Nature Communications 12 (1), 2224, 2021 | 10 | 2021 |
